Moreover, results of Bevacizumab [an anti-VEGF monoclonal antibody (mAb)] as first-line option in combination with chemotherapy were not confirmed by other anti-angiogenic agents, such as the tyrosine-kinase inhibitors (TKIs) axitinib (an anti-VEGFR TKI), sorafenib (anti-VEGFR2/3, platelet-derived growth factor receptor (PDGFR) and rapidly accelerated fibrosarcoma (RAF)/c-KIT), or imatinib mesylate (targeting BCR-ABL, c-KIT, and PDGFR) (38–41). Here, KIT is linked to fibrosarcoma.